Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

J.P. Morgan Adds Wyeth to 'Focus List'


J.P. Morgan added Wyeth (WYE) to its Focus List.

Analyst Carl Seiden says he sees growth accelerating from +10% in 2003 to +14% in both 2004 and 2005, vs. the industry average of +8% in 2003, and +14% in 2004 and 2005. Still, he notes that the stock is trading at a 20% discount to its peer group, at the bottom end of the group, and at a 10% discount to its 25-year historical average.

He says the Premarin family of drugs remains a negative; sales of the female hormone replacement product plunged after clinical trials showed an increased risk of ovarian cancer. Still, Seiden says Premarin is a risk that can be defined based on prescription trends. Wyeth also expects the FDA to approve a low-dose version of Premarin in the coming months.

Seiden notes the first quarter results were three cents above consensus, and four cents above his estimates. He says growth should be driven by a diversified, relatively new portfolio of in-line products.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus